NeoTRIP

NCT02620280 📎

Regimen

Experimental
Atezolizumab 1200 mg Q3W + nab-paclitaxel 125 mg/m2 D1,8 + carboplatin AUC2 D1,8 Q3W x 8 cycles preoperatively (no anthracycline), then surgery and AC-based adjuvant chemo.
Control
Nab-paclitaxel + carboplatin alone x 8 cycles, then AC adjuvant.

Population

Early high-risk (cT1cN1 or cT2-4aN0-3) or locally advanced triple-negative breast cancer.

Key finding

NeoTRIP failed to show pCR or EFS benefit from adding atezolizumab to carboplatin/nab-paclitaxel neoadjuvant without an anthracycline. Suggests anthracycline may be important for IO synergy in TNBC.

Source: PMID 35182721

Timeline

  • Publication: 2022 May

Guideline citations

  • NCCN BREAST